)
Climb Bio (CLYM) investor relations material
Climb Bio Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
The annual meeting is scheduled for June 5, 2026, and will be held virtually, with shareholders able to vote and submit questions online.
Shareholders of record as of April 7, 2026, are entitled to vote on four main proposals, including director elections and amendments to governance and compensation plans.
Proxy materials are distributed electronically to reduce costs and environmental impact, with paper copies available upon request.
Voting matters and shareholder proposals
Election of two Class II directors, Alexander (Bo) Cumbo and Douglas Williams, Ph.D., for three-year terms expiring at the 2029 annual meeting.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Approval of an amendment to the Certificate of Incorporation regarding the removal of directors for "cause."
Approval of an amendment to the 2021 Equity Incentive Plan to include prefunded warrants in the annual share pool increase calculation.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of seven members divided into three classes, with staggered three-year terms.
Majority of directors are independent under Nasdaq rules; CEO and Chair roles are separated.
Board committees include audit, compensation, and nominating/governance, all composed of independent directors.
Annual board and committee self-evaluations are conducted.
Director nomination process includes third-party search firms and stockholder recommendations.
- Multiple clinical readouts in 2026 will highlight differentiated B-cell therapies and pipeline progress.CLYM
Leerink Global Healthcare Conference 20269 Mar 2026 - Multiple clinical readouts expected in 2026 for novel mAbs targeting immune-mediated diseases.CLYM
Corporate presentation5 Mar 2026 - Clinical pipeline advanced, cash runway into 2028, and key data readouts expected in 2026.CLYM
Q4 20255 Mar 2026 - Multiple clinical readouts expected in 2024 for antibody therapies in PMN, ITP, and IgAN.CLYM
Oppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026 - Five clinical readouts in 2024 and strong cash runway drive autoimmune pipeline progress.CLYM
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026 - Multiple clinical readouts expected in 2026 for novel mAbs targeting immune-mediated diseases.CLYM
Investor Presentation8 Jan 2026 - Advancing monoclonal antibodies for immune diseases, with strong clinical data and robust financial support.CLYM
Leerink Global Healthcare Conference 202526 Dec 2025 - Advancing potent antibody therapies for immune diseases with key clinical milestones ahead.CLYM
TD Cowen 45th Annual Healthcare Conference18 Dec 2025 - 36.8M shares registered for resale post-acquisition; proceeds benefit selling stockholders.CLYM
Registration Filing16 Dec 2025
Next Climb Bio earnings date
Next Climb Bio earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage